Background: There is experimental evidence that targeted delivery of steroids to the inner ear can protect hearing during cochlear implant surgery. The best protection appears to be achieved through pre-treatment of the cochlea, but the time period required for treatment is long compared with the duration of surgery, and needs further optimization. The stability of hearing thresholds is determined over a 3-month period after hearing preservation cochlear implantation. Methods: Adult guinea pigs were implanted with a miniature cochlear implant electrode, and pure tone auditory brainstem response (ABR) thresholds were estimated in response to pure tones of 2–32 kHz immediately after surgery and at 1 week, 1 month and 3 months. Spiral ganglion cell (SGC) densities were estimated from mid-modular histological sections of the cochlea. Thirty minutes prior to implantation, a polymeric sponge (SeprapackTM, Genzyme) was loaded with either a 2% solution of dexamethasone phosphate or normal saline (control) and placed onto the round window. Results: Implantation was associated with an immediate elevation in thresholds across frequencies, with a full recovery below 2 kHz over the next week and a partial recovery of thresholds at higher frequencies. These thresholds remained unchanged for the next 3 months. There was an immediate and sustained reduction in the elevation of thresholds at 32 kHz in dexamethasone-treated animals. SGC densities were greater in steroid-treated animals than controls in the basal turn of the cochlea (at the region of implantation) 3 months after implantation. Conclusion: It is concluded that ABR thresholds remain stable for 3 months after cochlear implantation in the guinea pig, and that local application of steroids to the inner ear prior to implantation is an effective method of preserving SGC populations when there is residual hearing at the time of implantation.

Keywords:
Dexamethasone, Protection, Steroids, Targeted delivery, Inner ear
1.
Banerjee A, Parnes LS: Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005;26:878–881.
2.
Gouveris H, Selivanova O, Mann W: Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy. Eur Arch Otorhinolaryngol 2005;262:131–134.
3.
Plontke SK, Lowenheim H, Mertens J, Engel C, Meisner C, Weidner A, Zimmermann R, Preyer S, Koitschev A, Zenner HP: Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2009;119:359–369.
4.
Rauch SD: Intratympanic steroids for sensorineural hearing loss. Otolaryngol Clin North Am 2004;37:1061–1074.
5.
Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P, Segas J, Tzagaroulakis A, Ferekidis E: Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 2006;134:940–945.
6.
Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA: Intratympanic gentamicin for Meniere’s disease: a meta-analysis. Laryngoscope 2004;114:2085–2091.
7.
Gantz BJ, Turner C, Gfeller KE, Lowder MW: Preservation of hearing in cochlear implant surgery: advantages of combined electrical and acoustical speech processing. Laryngoscope 2005;115:796–802.
8.
Turner CW, Reiss LA, Gantz BJ: Combined acoustic and electric hearing: preserving residual acoustic hearing. Hear Res 2008;242: 164–171.
9.
Gantz BJ, Turner C: Combining acoustic and electrical speech processing: Iowa/nucleus hybrid implant. Acta Otolaryngol 2004;124:344–347.
10.
Lenarz T, Stover T, Buechner A, Paasche G, Briggs R, Risi F, Pesch J, Battmer RD: Temporal bone results and hearing preservation with a new straight electrode. Audiol Neurootol 2006;11(suppl 1):34–41.
11.
Gstoettner WK, van de Heyning P, O’Connor AF, Morera C, Sainz M, Vermeire K, McDonald S, Cavalle L, Helbig S, Valdecasas JG, Anderson I, Adunka OF: Electric acoustic stimulation of the auditory system: results of a multi-centre investigation. Acta Otolaryngol 2008;128:968–975.
12.
Lehnhardt E: Intracochlear placement of cochlear implant electrodes in soft surgery technique (article in German). HNO 1993;41:356–359.
13.
Briggs RJ, Tykocinski M, Stidham K, Roberson JB: Cochleostomy site: implications for electrode placement and hearing preservation. Acta Otolaryngol 2005;125:870–876.
14.
Gstoettner W, Kiefer J, Baumgartner WD, Pok S, Peters S, Adunka O: Hearing preservation in cochlear implantation for electric acoustic stimulation. Acta Otolaryngol 2004;124:348–352.
15.
James C, Albegger K, Battmer R, Burdo S, Deggouj N, Deguine O, Dillier N, Gersdorff M, Laszig R, Lenarz T, Rodriguez MM, Mondain M, Offeciers E, Macias AR, Ramsden R, Sterkers O, Von Wallenberg E, Weber B, Fraysse B: Preservation of residual hearing with cochlear implantation: how and why. Acta Otolaryngol 2005;125:481–491.
16.
Kiefer J, Gstoettner W, Baumgartner W, Pok SM, Tillein J, Ye Q, von Ilberg C: Conservation of low-frequency hearing in cochlear implantation. Acta Otolaryngol 2004;124:272–280.
17.
Banerjee A, Hawthorne MR, Flood LM, Martin FW: Audit of stapedectomy results in a district general hospital. Clin Otolaryngol Allied Sci 2002;27:275–278.
18.
De La Cruz A, Fayad JN: Revision stapedectomy. Otolaryngol Head Neck Surg 2000;123:728–732.
19.
Mann WJ, Amedee RG, Fuerst G, Tabb HG: Hearing loss as a complication of stapes surgery. Otolaryngol Head Neck Surg 1996;115:324–328.
20.
Sargent EW: The learning curve revisited: stapedotomy. Otolaryngol Head Neck Surg 2002;126:20–25.
21.
Yung MW, Oates J, Vowler SL: The learning curve in stapes surgery and its implication to training. Laryngoscope 2006;116:67–71.
22.
Gstoettner WK, Helbig S, Maier N, Kiefer J, Radeloff A, Adunka OF: Ipsilateral electric acoustic stimulation of the auditory system: results of long-term hearing preservation. Audiol Neurootol 2006;11(suppl 1):49–56.
23.
Eshraghi AA, Adil E, He J, Graves R, Balkany TJ, Van De Water TR: Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol Neurotol 2007;28:842–849.
24.
James DP, Eastwood H, Richardson RT, O’Leary SJ: Effects of round window dexamethasone on residual hearing in a guinea pig model of cochlear implantation. Audiol Neurootol 2008;13:86–96.
25.
Ye Q, Tillein J, Hartmann R, Gstoettner W, Kiefer J: Application of a corticosteroid (triamcinolon) protects inner ear function after surgical intervention. Ear Hear 2007;28:361–369.
26.
Vivero RJ, Joseph DE, Angeli S, He J, Chen S, Eshraghi AA, Balkany TJ, Van de Water TR: Dexamethasone base conserves hearing from electrode trauma-induced hearing loss. Laryngoscope 2008;118:2028–2035.
27.
De Ceulaer G, Johnson S, Yperman M, Daemers K, Offeciers FE, O’Donoghue GM, Govaerts PJ: Long-term evaluation of the effect of intracochlear steroid deposition on electrode impedance in cochlear implant patients. Otol Neurotol 2003;24:769–774.
28.
Paasche G, Bockel F, Tasche C, Lesinski-Schiedat A, Lenarz T: Changes of postoperative impedances in cochlear implant patients: the short-term effects of modified electrode surfaces and intracochlear corticosteroids. Otol Neurotol 2006;27:639–647.
29.
Chang A, Eastwood H, Sly D, James D, Richardson R, O’Leary S: Factors influencing the efficacy of round window dexamethasone protection of residual hearing post-cochlear implant surgery. Hear Res 2009;255:67–72.
30.
Salt AN, Ma Y: Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 2001;154:88–97.
31.
Shepherd RK, Coco A, Epp SB: Neurotrophins and electrical stimulation for protection and repair of spiral ganglion neurons following sensorineural hearing loss. Hear Res 2008;242:100–109.
32.
Hirose K, Discolo CM, Keasler JR, Ransohoff R: Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma. J Comp Neurol 2005;489:180–194.
33.
Hirose K, Liberman MC: Lateral wall histopathology and endocochlear potential in the noise-damaged mouse cochlea. J Assoc Res Otolaryngol 2003;4:339–352.
34.
Kopke R, Allen KA, Henderson D, Hoffer M, Frenz D, Van de Water T: A radical demise: toxins and trauma share common pathways in hair cell death. Ann NY Acad Sci 1999;884:171–191.
35.
Liberman MC, Kiang NY: Acoustic trauma in cats: cochlear pathology and auditory-nerve activity. Acta Otolaryngol Suppl 1978;358:1–63.
36.
Tornabene SV, Sato K, Pham L, Billings P, Keithley EM: Immune cell recruitment following acoustic trauma. Hear Res 2006;222:115–124.
37.
Fredelius L: Time sequence of degeneration pattern of the organ of Corti after acoustic overstimulation: a transmission electron microscopy study. Acta Otolaryngol 1988;106:373–385.
38.
Fredelius L, Rask-Andersen H, Johansson B, Urquiza R, Bagger-Sjoback D, Wersall J: Time sequence of degeneration pattern of the organ of Corti after acoustic overstimulation: a light microscopical and electrophysiological investigation in the guinea pig. Acta Otolaryngol 1988;106:81–93.
39.
Ohlemiller KK, Wright JS, Dugan LL: Early elevation of cochlear reactive oxygen species following noise exposure. Audiol Neurootol 1999;4:229–236.
40.
Adunka O, Unkelbach MH, Mack M, Hambek M, Gstoettner W, Kiefer J: Cochlear implantation via the round window membrane minimizes trauma to cochlear structures: a histologically controlled insertion study. Acta Otolaryngol 2004;124:807–812.
41.
Clark GM, Shute SA, Shepherd RK, Carter TD: Cochlear implantation: osteoneogenesis, electrode-tissue impedance, and residual hearing. Ann Otol Rhinol Laryngol Suppl 1995;166:40–42.
42.
Eshraghi AA, Yang NW, Balkany TJ: Comparative study of cochlear damage with three perimodiolar electrode designs. Laryngoscope 2003;113:415–419.
43.
Gstoettner W, Hamzavi J, Franz P, Plenk H Jr, Czerny C, Susani M, Adunka O, Baumgartner WD: Intracochlear position of cochlear implant electrodes (in German). Wien Klin Wochenschr 2000;112:477–480.
44.
Fayad J, Linthicum FH Jr, Otto SR, Galey FR, House WF: Cochlear implants: histopathologic findings related to performance in 16 human temporal bones. Ann Otol Rhinol Laryngol 1991;100:807–811.
45.
Nadol JB Jr, Shiao JY, Burgess BJ, Ketten DR, Eddington DK, Gantz BJ, Kos I, Montandon P, Coker NJ, Roland JT Jr, Shallop JK: Histopathology of cochlear implants in humans. Ann Otol Rhinol Laryngol 2001;110:883–891.
46.
Welling DB, Hinojosa R, Gantz BJ, Lee JT: Insertional trauma of multichannel cochlear implants. Laryngoscope 1993;103:995–1001.
47.
Hara M, Nomura Y, Saito K: Histopathologic study of the perilymph-suctioned labyrinth. Ann Otol Rhinol Laryngol 1990;99:316–320.
48.
Kiefer J, Bohnke F, Adunka O, Arnold W: Representation of acoustic signals in the human cochlea in presence of a cochlear implant electrode. Hear Res 2006;221:36–43.
49.
Adunka O, Roush P, Grose J, Macpherson C, Buchman CA: Monitoring of cochlear function during cochlear implantation. Laryngoscope 2006;116:1017–1020.
50.
Eshraghi AA, Polak M, He J, Telischi FF, Balkany TJ, Van De Water TR: Pattern of hearing loss in a rat model of cochlear implantation trauma. Otol Neurotol 2005;26:442–447, discussion 447.
51.
Eshraghi AA, Van de Water TR: Cochlear implantation trauma and noise-induced hearing loss: apoptosis and therapeutic strategies. Anat Rec A Discov Mol Cell Evol Biol 2006;288:473–481.
52.
Evans P, Halliwell B: Free radicals and hearing: cause, consequence, and criteria. Ann NY Acad Sci 1999;884:19–40.
53.
Henderson D, McFadden SL, Liu CC, Hight N, Zheng XY: The role of antioxidants in protection from impulse noise. Ann NY Acad Sci 1999;884:368–380.
54.
Rybak LP, Whitworth CA: Ototoxicity: therapeutic opportunities. Drug Discov Today 2005;10:1313–1321.
55.
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157–167.
56.
Adams JC: Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002;23:316–322.
57.
Harris JP, Fukuda S, Keithley EM: Spiral modiolar vein: its importance in inner ear inflammation. Acta Otolaryngol 1990;110:357–365.
58.
Ichimiya I, Yoshida K, Hirano T, Suzuki M, Mogi G: Significance of spiral ligament fibrocytes with cochlear inflammation. Int J Pediatr Otorhinolaryngol 2000;56:45–51.
59.
Ichimiya I, Yoshida K, Suzuki M, Mogi G: Expression of adhesion molecules by cultured spiral ligament fibrocytes stimulated with proinflammatory cytokines. Ann Otol Rhinol Laryngol 2003;112:722–728.
60.
Ma C, Billings P, Harris JP, Keithley EM: Characterization of an experimentally induced inner ear immune response. Laryngoscope 2000;110:451–456.
61.
Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM: Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope 2002;112:1627–1634.
62.
Klis SF, O’Leary SJ, Hamers FP, De Groot JC, Smoorenburg GF: Reversible cisplatin ototoxicity in the albino guinea pig. Neuroreport 2000;11:623–626.
63.
Sluyter S, Klis SF, de Groot JC, Smoorenburg GF: Alterations in the stria vascularis in relation to cisplatin ototoxicity and recovery. Hear Res 2003;185:49–56.
64.
Tsukasaki N, Whitworth CA, Rybak LP: Acute changes in cochlear potentials due to cisplatin. Hear Res 2000;149:189–198.
65.
Do K, Baker K, Praetrius M, Staecker H: A mouse model of implantation trauma. Int Congr Ser 2004;1273:167–170.
66.
Wei BP, Mubiru S, O’Leary S: Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2006:CD003998.
67.
Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, Bense S, Theil D, Jahn K, Brandt T: Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004;351:354–361.
68.
Paasche G, Tasche C, Stover T, Lesinski-Schiedat A, Lenarz T: The long-term effects of modified electrode surfaces and intracochlear corticosteroids on postoperative impedances in cochlear implant patients. Otol Neurotol 2009;30:592–598.
69.
Huang CQ, Tykocinski M, Stathopoulos D, Cowan R: Effects of steroids and lubricants on electrical impedance and tissue response following cochlear implantation. Cochlear Implants Int 2007;8:123–147.
70.
Jonas JB: Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38:218–245.
71.
Plontke SK, Mikulec AA, Salt AN: Rapid clearance of methylprednisolone after intratympanic application in humans. Comment on: Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124–30. Otol Neurotol 2008;29:732–733, author reply 733.
72.
Rosenfeld PJ, Rich RM, Lalwani GA: Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361–372.
73.
Arnold W, Bredberg G, Gstottner W, Helms J, Hildmann H, Kiratzidis T, Muller J, Ramsden RT, Roland P, Walterspiel JN: Meningitis following cochlear implantation: pathomechanisms, clinical symptoms, conservative and surgical treatments. ORL J Otorhinolaryngol Relat Spec 2002;64:382–389.
74.
Reefhuis J, Honein MA, Whitney CG, Chamany S, Mann EA, Biernath KR, Broder K, Manning S, Avashia S, Victor M, Costa P, Devine O, Graham A, Boyle C: Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003;349:435–445.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.